Rigel Pharmaceuticals, Inc. announced that it has appointed Michael P. Miller to its Board of Directors. Michael P. Miller joined Rigel's Board of Directors as an independent director and member of the Board of Directors' Compensation Committee, effective February 1, 2026. Mr. Miller has more than four decades of experience in commercial and leadership roles in the biotechnology and pharmaceutical industries.
Mr. Miller currently serves on the Board of Directors at Puma Biotechnology and BioXcel Therapeutics. He served as the Executive Vice President of U.S. Commercial of Jazz Pharmaceuticals from April 2014 until his retirement in September 2020. Before that, Mr. Miller was Senior Vice President and Chief Commercial Officer of Vivus.
Prior to that, Mr. Miller served as Vice President, leading the HER Family Oncology franchise, of Genentech. Other roles included Senior Vice President, Chief Commercial Officer of Connetics Corporation, a specialty pharmaceutical company acquired by Stiefel Laboratories (GSK); Vice President of the of ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson; and various sales and marketing positions at Syntex Corporation. Mr. Miller earned a B.S. in Business Administration and Finance from the University of San Francisco and an M.B.A. in Information and Computer Systems from San Francisco State University.
